Skip to content

Study · Randomized controlled trial · n = 135 · 1996

3 results

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.

Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F

Cancer1 Oct 1996Cited by 43 (Europe PMC)

PMID8839551 (opens in a new tab)DOI10.1002/(sici)1097-0142(19961001)78:7<1452::aid-cncr12>3.0.co;2-z (opens in a new tab)PepBankPUB-08839551
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In advanced ovarian carcinoma, progression-free survival did not differ significantly between triptorelin and placebo with standard chemotherapy.

    In plain wordsIn advanced ovarian cancer, progression-free survival was similar with triptorelin and placebo alongside standard chemotherapy.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeProgression-free survival
    Study

    n = 135

    Comparator
    Placebo with standard chemotherapy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.75 mg monthlyAs given in this study (human).

    Source sentences

    Summary
    However, their progression free and overall survival were not significantly different from that of patients receiving placebo injections (statistical power > 80% for a difference between both groups of > or = 20%).
    3 context sentences
    Summary · context
    One hundred and thirty-five patients with Stage III or IV epithelial ovarian carcinoma participated in this prospective randomized double blind trial.
    Summary · context
    After cytoreductive surgery, 69 patients received monthly injections of a depot preparation of the LHRH agonist [D-Trp6] LHRH (triptorelin, 3.75 mg) and 66 patients received placebo until their deaths or termination of trial, respectively.
    Summary · context
    All patients were treated with a standard platinum-based chemotherapy, and, if necessary, with second- or third-line cytotoxic regimens.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In advanced ovarian carcinoma, overall survival did not differ significantly between triptorelin and placebo with standard chemotherapy.

    In plain wordsIn advanced ovarian cancer, overall survival was similar with triptorelin and placebo alongside standard chemotherapy.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOverall survival
    Study

    n = 135

    Comparator
    Placebo with standard chemotherapy
    Outcome group
    Mortality · Cancer
    Studied dose
    3.75 mg monthlyAs given in this study (human).

    Source sentences

    Summary
    However, their progression free and overall survival were not significantly different from that of patients receiving placebo injections (statistical power > 80% for a difference between both groups of > or = 20%).
    3 context sentences
    Summary · context
    One hundred and thirty-five patients with Stage III or IV epithelial ovarian carcinoma participated in this prospective randomized double blind trial.
    Summary · context
    After cytoreductive surgery, 69 patients received monthly injections of a depot preparation of the LHRH agonist [D-Trp6] LHRH (triptorelin, 3.75 mg) and 66 patients received placebo until their deaths or termination of trial, respectively.
    Summary · context
    All patients were treated with a standard platinum-based chemotherapy, and, if necessary, with second- or third-line cytotoxic regimens.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In advanced ovarian carcinoma, triptorelin reliably suppressed endogenous gonadotrophins.

    In plain wordsIn advanced ovarian cancer, triptorelin suppressed natural gonadotrophins.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseEndogenous gonadotrophin suppression
    Study

    n = 69

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg monthlyAs given in this study (human).

    Source sentences

    Summary
    Endogenous gonadotrophins were reliably suppressed in patients treated with triptorelin.
    3 context sentences
    Summary · context
    One hundred and thirty-five patients with Stage III or IV epithelial ovarian carcinoma participated in this prospective randomized double blind trial.
    Summary · context
    After cytoreductive surgery, 69 patients received monthly injections of a depot preparation of the LHRH agonist [D-Trp6] LHRH (triptorelin, 3.75 mg) and 66 patients received placebo until their deaths or termination of trial, respectively.
    Summary · context
    All patients were treated with a standard platinum-based chemotherapy, and, if necessary, with second- or third-line cytotoxic regimens.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.